Baricitinib(巴瑞替尼)的适应症和禁忌症是什么,Baricitinib(Baricitinib)适用于：1、对一种或多种TNF受体阻滞剂反应不足的中度至重度活动性类风湿性关节炎成人患者的治疗；2、需要补充氧气、无创或有创机械通气(ECMO)的住院成人的COVID-19(新冠病毒)治疗；3、成人重度斑秃患者的治疗。
Baricitinib (巴瑞替尼) is a medication that has been approved for the treatment of several conditions, including rheumatoid arthritis, COVID-19, and alopecia areata. However, it is important to note that the use of Baricitinib is subject to certain indications and contraindications. This article aims to provide accurate information about the indications and contraindications of Baricitinib.
1. Indications of Baricitinib:
Baricitinib is indicated for the following conditions:
1.1 Rheumatoid Arthritis: Baricitinib is approved for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). It works by inhibiting certain enzymes involved in the inflammatory response, thereby reducing joint inflammation and improving symptoms.
1.2 COVID-19: Baricitinib received emergency use authorization to be used in combination with remdesivir for the treatment of hospitalized adults and pediatric patients (2 years of age and older) with suspected or laboratory-confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). It can help reduce the risk of disease progression and the need for ventilation support.
1.3 Alopecia Areata: Baricitinib has shown promise in the treatment of alopecia areata, an autoimmune condition that causes hair loss in patches. However, its use for this indication is still under investigation, and further research is needed to establish its effectiveness.
2. Contraindications of Baricitinib:
Baricitinib is contraindicated in the following situations:
2.1 Hypersensitivity: Individuals with a known hypersensitivity to Baricitinib or any of its components should not use this medication.
2.2 Pregnancy: Baricitinib may cause fetal harm when administered to pregnant women. Therefore, it is contraindicated during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least one week after the last dose of Baricitinib.
2.3 Severe Hepatic Impairment: Baricitinib should not be used in patients with severe hepatic impairment (Child-Pugh class C). The safety and effectiveness of Baricitinib in these patients have not been established.
2.4 Active Tuberculosis: Baricitinib should not be initiated in patients with active tuberculosis due to the risk of exacerbating the infection. Prior to starting treatment, a screening for tuberculosis should be performed.
2.5 Live Vaccines: The use of live vaccines should be avoided during treatment with Baricitinib.
In conclusion, Baricitinib is a medication with multiple indications, including rheumatoid arthritis, COVID-19, and alopecia areata. However, it is contraindicated in individuals with hypersensitivity to the drug, during pregnancy, in patients with severe hepatic impairment, and in those with active tuberculosis. It is important to understand and adhere to the indications and contraindications of Baricitinib to ensure safe and effective use of the medication. As always, it is recommended to consult a healthcare professional for personalized advice and guidance regarding the use of Baricitinib or any other medication.
